- Home
- RDCM vs ZURA Comparison
RDCM vs ZURA Comparison
Compare RDCM & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDCM | ZURA |
|---|---|---|
| Founded | 1985 | 2022 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.2M | 252.9M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | RDCM | ZURA |
|---|---|---|
| Price | $13.41 | $4.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $18.00 | $11.38 |
| AVG Volume (30 Days) | 76.8K | ★ 369.0K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.57 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $68,901,000.00 | N/A |
| Revenue This Year | $18.86 | N/A |
| Revenue Next Year | $11.39 | N/A |
| P/E Ratio | $20.99 | ★ N/A |
| Revenue Growth | ★ 17.27 | N/A |
| 52 Week Low | $9.88 | $0.97 |
| 52 Week High | $15.98 | $4.68 |
Technical Indicators
Market Signals| Indicator | RDCM | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 62.87 |
| Support Level | $12.81 | $3.88 |
| Resistance Level | $13.88 | $4.45 |
| Average True Range (ATR) | 0.41 | 0.25 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 62.06 | 79.37 |
Price Performance
Historical ComparisonAbout RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.